

PC-3 Xenograft Study 1 (P-PPr-01-2015)
Median Tumor Volume: Day 1 - 60
Error Bars = +/- 1 SEM; mean tumor size data for groups with < 50% survival not presented
Median Tumor Volume (mm³)
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
45
50
55
60
Day
Group 1: Vehicle 0 mg/kg, itu qwk x 3
Group 2: NanoPac 37.5 mg/kg, itu, qwk x 1
Group 3: NanoPac 12.5 mg/kg, itu, qwk x 3
Group 4: NanoPac 37.5 mg/kg, itu, qwk x 3
Group 5: Paclitaxel 30 mg/kg, iv qwk x 3

Figure 1



PC-3 Xenograft Study 2 (PD-PPy-02-2016)
Mean Tumor Volume: Day 1 - 60
Error Bars = +/- 1 SEM; mean tumor size data for groups with < 50% survival not presented
Mean Tumor Volume (mm³)
Day
0
200
400
600
800
1000
1200
1400
1600
1800
2000
0
5
10
15
20
25
30
35
40
45
50
55
60
Group 1: Vehicle 0 mg/kg, IT qwk x 3
Group 2: NanoDoce 100 mg/kg, IT qwk x 1
Group 3: NanoDoce 37.5 mg/kg, IT qwk x 3
Group 4: NanoDoce 100 mg/kg, IT qwk x 3
Group 5: NanoPac 37.5 mg/kg, IT qwk x 3
Group 6: Docetaxel 30 mg/kg, IV qwk x 3

Figure 2



MDA-MB-231 Xenograft Study 2 (PD-PB-04-2016)
Mean Tumor Volume Day 1 - 49
Error Bars = +/- 1 SEM; mean tumor size data for groups with <50% survival not presented
Tumor Volume (mm³)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
45
50
Day
Group 1: Vehicle 0 mg/kg, IT qwk x 3
Group 2: NanoPac 100 mg/kg, IT qwk x 3
Group 3: NanoDoce 100 mg/kg, IT qwk x 3
Group 4: Docetaxel 30 mg/kg, IV qwk x 3
Group 5: Paclitaxel 30 mg/kg, IV qwk x 3

Figure 3



MX-1 Xenograft Study 2 (P-PB-03-2016)
Mean Tumor Volume: Day 1 - 54
Error Bars = 1 +/- SEM; mean tumor size data for groups with <50% survival not presented
Tumor Volume (mm³)
Day
Group 1: Vehicle 0 mg/kg, IT qwk x 3
Group 2: NanoPac 100 mg/kg, IT qwk x 3
Group 3: NanoDoce 100 mg/kg, IT qwk x 3
Group 4: Docetaxel 30 mg/kg, IV qwk x 3
Group 5: Paclitaxel 30 mg/kg, IV qwk x 3

Figure 4